ID
41679
Descrição
The primary objective of this study was to demonstrate bioequivalence between eltrombopag oral film-coated tablets manufactured at Research and Development (R&D) and Commercial sites. The subject participants each went through two dosing periods (Period 1 and Period 2), during each of which they received a single dose of eltrombopag. The dosing periods were separated by a washout of at least 10 days. For each period, subjects had to perform a visit on the day before and one on the day of the administration of the drug. Furthermore, the protocol-defined visits included a screening visit and a follow-up visit. Study ID: 105122 Clinical Study ID: 105122 Study Title: Phase I Bioequivalence Study for SB 497115 GR Phase II and Phase III Tablets Sponsor: GlaxoSmithKline Phase: phase 1 Study Recruitment Status: Completed Generic Name: Eltrombopag Study Indication: Thrombocytopenia This form has to be filled out at the Follow-Up Visit.
Palavras-chave
Versões (1)
- 12/12/2020 12/12/2020 -
Titular dos direitos
GlaxoSmithKline
Transferido a
12 de dezembro de 2020
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
GSK Eltrombopag Thrombocytopenia, Clinical Study ID: 105122
Vital Signs, Follow-Up
- StudyEvent: ODM
Similar models
Vital Signs, Follow-Up
- StudyEvent: ODM
C0011008 (UMLS CUI [1,2])
C0518766 (UMLS CUI [2,1])
C0040223 (UMLS CUI [2,2])